I welcome the witnesses who are joining us for the second hour of the hearing.
Ms. Michaud, I'll start with you. You mention that only 4% of immunotherapy clinical trials in Canada are based on innovation developed here. Is this an indicator that research isn't necessarily the problem, but rather, our inability to fund the transition to clinical trials?